HH&L Acquisition Co.

HH&L Acquisition Co.

HHLA-UN
HH&L Acquisition Co.US flagNew York Stock Exchange
10.83
USD
+0.08
- -
156.83MMarket Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChatGPT
CEO
Qi Li
Sector
Financial Services
Industry
Shell Companies
Address
York House, The Landmark Central Hong Kong
IPO Date
Feb 5, 2021
Website
hopuhl.com
Business
HH&L Acquisition Co. HH&L Acquisition Co. is a blank check company incorporated in the Cayman Islands whose principal business activity is to pursue a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company focuses on healthcare or healthcare-related companies in Asian markets, particularly the Greater China region, or global healthcare firms with significant growth potential in Greater China or Asia; it does not currently generate revenue from operations or offer products or services beyond its SPAC structure. Headquartered in Hong Kong and founded in 2020, HH&L Acquisition Co. operates globally with an emphasis on Asian target markets and held approximately $414 million in trust proceeds from its initial public offering completed in February 2021. In October 2022, the company entered into a definitive business combination agreement with DiaCarta Ltd., a precision molecular diagnostics firm developing oncology and infectious disease tests, under which HH&L would domesticate to Delaware, acquire DiaCarta in a merger valuing it at a pre-money equity of $460 million, and rename itself DiaCarta Inc., though the transaction terminated mutually in July 2023. Following the failed merger, HH&L Acquisition Co. liquidated in February 2024, redeeming shares from trust at $10.79 per share and ceasing active operations as a SPAC.